Yongsheng S. Li

Chongqing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 125 publications

Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.

Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 24, 2026

Multi-tissue transcriptomic atlas reveals systemic effects of FGF19 on metabolism and immunity.

Multi-tissue transcriptomic atlas reveals systemic effects of FGF19 on metabolism and immunity.

Journal: Biochemical pharmacology

Published: June 05, 2026

Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC: The ACTIVE Trial.

Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC: The ACTIVE Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: April 24, 2026

MRPL47 as a Novel Mitochondrial Biomarker for Early Detection and Therapeutic Response in Ovarian Cancer.

MRPL47 as a Novel Mitochondrial Biomarker for Early Detection and Therapeutic Response in Ovarian Cancer.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 04, 2026

Harnessing Neutrophil Plasticity: From Mechanistic Insights to Oncology Therapeutics.

Harnessing Neutrophil Plasticity: From Mechanistic Insights to Oncology Therapeutics.

Journal: Cancer letters

Published: January 14, 2026

Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study.

Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study.

Journal: Experimental hematology & oncology

Published: December 23, 2025

Targeting cholesterol metabolism: a core regulator of tumor-associated macrophage plasticity and immunotherapy response.

Targeting cholesterol metabolism: a core regulator of tumor-associated macrophage plasticity and immunotherapy response.

Journal: Biochimica et biophysica acta. Reviews on cancer

Published: December 06, 2025

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 01, 2025

Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8+ T cells.

Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8+ T cells.

Journal: Journal for immunotherapy of cancer

Published: November 01, 2025

Correction: Case Report: Curative effect and mechanism of surufatinib combined with toripalimab in the treatment of 1 case of lung large-cell neuroendocrine carcinoma.

Correction: Case Report: Curative effect and mechanism of surufatinib combined with toripalimab in the treatment of 1 case of lung large-cell neuroendocrine carcinoma.

Journal: Frontiers in oncology

Published: October 22, 2025

MTAP deficiency enhances collective metastasis in non-small cell lung cancer via WNT3A methylation.

MTAP deficiency enhances collective metastasis in non-small cell lung cancer via WNT3A methylation.

Journal: Oncogene

Published: October 16, 2025

Showing 1-12 of 125

Last Updated: 09/26/2026